Business
Publication of Annual Report and notice of AGM
Publication of Annual Report and notice of AGM.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 1267U Allergy Therapeutics PLC 19 October 2017 \n\n19 October 2017\n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \n \nANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING\n \n \nAllergy Therapeutics Plc has today published the following documents:\n \n· Annual Report for the year ended 30 June 2017 (\"Annual Report\"); and\n \n· Notice of 2017 Annual General Meeting (\"Notice of Meeting\"); \n \nEach of these documents is available electronically on the Company's website at www.allergytherapeutics.com \n \nA hard copy of the Annual Report and Notice of Meeting is anticipated to be posted to shareholders on 19 October 2017. \n \n \n- ENDS -\n \n \n \n \n \nFor further information, please contact:\n \nAllergy Therapeutics\n+44 (0) 1903 845 820\nManuel Llobet, Chief Executive Officer\nNick Wykeman, Finance Director\n \nPanmure Gordon\n+44 (0) 20 7886 2500\nFreddy Crossley / Duncan Monteith, Corporate Finance\nTom Salvesen, Corporate Broking\n \nConsilium Strategic Communications\n+44 20 3709 5700\nMary-Jane Elliott / Ivar Milligan / Philippa Gardner\[email protected]\n \nNotes for editors:\n \nAbout Allergy Therapeutics\n \nAllergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.\n \nFormed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is...